Mills Roger reported both an award and disposal of 392,837 Addex Therapeutics shares on September 2, leaving him with 785,976 shares after the award. The transaction also covered 50,000 derivative securities, with post-transaction ownership moving from zero after disposal to 50,000 after the award, giving investors specific updated ownership figures.

Key Highlights

  • Mills Roger’s post-transaction Addex share ownership was listed as 393,139 after the disposal.
  • The transaction included 50,000 derivative securities, with ownership recorded at 50,000 after the award.
  • Mills Roger is Addex Therapeutics’ chief medical officer.

Mills Roger, chief medical officer of Addex Therapeutics Ltd. reported an award and disposal involving 392,837 Addex shares on September 2, 2026. His post-transaction shareholding was recorded at 785,976 following the award.

Addex Share Transactions Recorded

The disposal left Mills Roger with 393,139 Addex shares. A separate award of 392,837 shares was also recorded, after which his ownership stood at 785,976 shares. The transaction date for both share entries was September 2, 2026. The reported figures identify separate post-transaction ownership positions tied to the disposal and award.

Derivative Securities Ownership Updated

Mills Roger also disposed of 50,000 Addex derivative securities, with ownership shown as zero after that transaction. A separate award of 50,000 derivative securities followed, leaving him with 50,000 derivative securities. The share and derivative-security entries each included both a disposal and an award. The reported post-transaction figures were 393,139 and 785,976 shares, alongside zero and 50,000 derivative securities.